Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Sihuan Pharmaceutical (460 HK): Buybacks, Now A Spin-Off

Sihuan Pharma (460 HK): On Xuanzhu Biopharm's Imminent Spin-Off

Quiddity Advisors

Event-Driven

Sihuan Pharmaceutical Hldgs / Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sihuan-pharmaceutical-hldgs" target="_blank" data-smartkarma-citation="entities:33:1" rel="noopener"><strong>Sihuan Pharmaceutical (460 HK)</strong></a> has shot down rumours that it is under negotiation with potential investors in respect of privatisation.</li>
<li>Reportedly SOE China Resources is in talks with Sihuan Pharma's chairman in a deal valuing the company at US$3bn or a 114% premium to the current price. </li>
<li>The logic of a privatisation makes sense. I would not be so quick to dismiss the denial. Plus Sihuan Pharma is very cash-rich.</li>
</ul>



Sihuan Pharmaceutical (460 HK) has shot down rumours that it is under negotiation with potential investors in respect of privatisation.
Reportedly SOE China Resources is in talks with Sihuan Pharma's chairman in a deal valuing the company at US$3bn or a 114% premium to the current price. 
The logic of a privatisation makes sense. I would not be so quick to dismiss the denial. Plus Sihuan Pharma is very cash-rich.


Sihuan Pharma (460 HK) Denies China Resources Approach